Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $383.00.

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

Amgen is also targeting 2024 revenue growth of around 18%, projecting confidence in the significant opportunities ahead. Beyond the products currently on the market, Amgen benefits from a pipeline ...

Amgen Inc.'s Q3 earnings — due 30th October ... I'd advise readers to pay close attention to these products' performance in Q3. I have their contribution to revenues rising from nearly $12bn ...

Are you a print subscriber? Activate your account. By Mikey Garcia - 41 min 54 sec ago By Adrianne Pasquarelli - 1 hour 4 min ago By Ad Age and Creativity Staff - 1 hour 13 min ago By Brandon ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...